

Urinary Tract Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Urethritis, Cystitis, Pyelonephritis), By End use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Others), By Region and Competition

<https://marketpublishers.com/r/U1DC12808B6CEN.html>

Date: January 2024

Pages: 190

Price: US\$ 4,900.00 (Single User License)

ID: U1DC12808B6CEN

Abstracts

Global Urinary Tract Infection Testing Market was valued at USD 561.32 Million in 2022 and is anticipated to project steady growth in the forecast period with a CAGR of 4.25% through 2028. Urinary tract infections (UTIs) are a common ailment affecting millions of individuals worldwide, with a substantial economic and healthcare burden. Accurate and timely diagnosis is crucial for effective treatment and patient care. This need has driven the growth of the global Urinary Tract Infection Testing Market. Urinary tract infections occur when harmful bacteria enter the urinary system and multiply, leading to various symptoms such as pain and discomfort during urination, frequent urges to urinate, and in some cases, fever. UTIs can affect any part of the urinary system, including the bladder, urethra, and kidneys. Rapid and accurate diagnosis of UTIs is essential to determine the appropriate treatment regimen, which typically involves antibiotics.

The global urinary tract infection testing market has witnessed significant growth in recent years, driven by various factors, including rising UTI incidence, increasing awareness among patients and healthcare professionals, and technological advancements in diagnostic tests. The market size is expected to reach a substantial figure, with projections suggesting steady growth in the coming years. The COVID-19 pandemic has also underscored the importance of rapid diagnostic testing, which has further contributed to the demand for UTI testing.

The shift towards point-of-care testing is a significant trend in the UTI testing market. Point-of-care tests provide quick results, enabling healthcare providers to initiate treatment promptly. Innovations in diagnostic technologies, such as nucleic acid amplification tests and advanced urine analyzers, have improved the accuracy and efficiency of UTI testing. Home testing kits for UTIs are becoming more popular, giving patients the convenience to monitor their health from the comfort of their homes. This trend has gained momentum due to the COVID-19 pandemic, as people seek to minimize healthcare facility visits. Developing countries are witnessing an increase in healthcare awareness and infrastructure, leading to substantial growth in UTI testing markets in these regions.

Key Market Drivers

Rising Urinary tract infections Incidence Rates is Driving the Global Urinary Tract Infection Testing Market

Urinary tract infections (UTIs) are one of the most common bacterial infections worldwide, affecting millions of people each year. While UTIs are typically not life-threatening, they can cause significant discomfort and inconvenience. Moreover, if left untreated, they can lead to more severe health complications. Recent years have seen a notable rise in UTI incidence rates, creating a demand for more efficient diagnostic tools and increasing the global Urinary Tract Infection Testing Market. UTIs are bacterial infections that can affect any part of the urinary system, including the bladder, urethra, and kidneys. The majority of UTIs are caused by *Escherichia coli* (*E. coli*) bacteria, but other bacteria can also be responsible. Common symptoms of UTIs include frequent urination, a burning sensation during urination, cloudy or bloody urine, and discomfort in the lower abdomen. Verse and misuse of antibiotics have led to the emergence of antibiotic-resistant strains of bacteria, making UTIs harder to treat. The rising prevalence of multidrug-resistant UTIs necessitates more accurate and prompt diagnosis. Modern lifestyles, such as increased sexual activity and the use of certain types of birth control, can contribute to an increased risk of UTIs. As the global population continues to age, older individuals become more susceptible to UTIs due to weakened immune systems and other age-related factors. Improved education and awareness regarding the symptoms and risks of UTIs may lead to more people seeking medical attention for these infections.

The demand for accurate and efficient UTI diagnostic tools has given rise to a thriving Urinary Tract Infection Testing Market. This market includes a wide range of products

and services. Traditional urinalysis remains the most common method for diagnosing UTIs. However, advances in urinalysis techniques have allowed for more accurate and rapid results. Dipstick tests are cost-effective and easy-to-use tools for initial UTI screening. They can quickly detect key indicators of infection, such as nitrites and leukocytes. For complex or recurrent UTIs, microbiological culture tests are crucial for identifying the specific bacteria causing the infection and their antibiotic susceptibility. Advanced technology has made these tests more efficient and precise. Molecular testing methods, like polymerase chain reaction (PCR), can detect UTIs with high sensitivity and specificity. These tests can identify the presence of bacteria and even antibiotic resistance genes. Point-of-Care Testing (POCT) devices have gained popularity as they offer rapid results, allowing healthcare providers to initiate treatment more promptly.

Growing Private and Public Sector Investments is Driving the Global Urinary Tract Infection Testing Market

Private sector investments have been a driving force behind the growth of the global UTI testing market. Pharmaceutical and diagnostic companies have recognized the potential for developing innovative solutions to diagnose and manage UTIs more effectively. These investments are directed towards research and development to create advanced diagnostic tests, antibiotics, and therapeutics to treat UTIs. Companies are increasingly focusing on the development of rapid diagnostic tests that offer quicker and more accurate results, enabling healthcare providers to initiate treatment promptly. For instance, the advent of molecular diagnostics and point-of-care testing devices has revolutionized the way UTIs are diagnosed and managed. These innovations offer higher sensitivity and specificity, reducing the chances of misdiagnosis and unnecessary antibiotic prescriptions. Moreover, private sector investments are also supporting the development of alternative therapies, such as novel antibiotics, which can target drug-resistant UTI-causing bacteria. The rise of antibiotic-resistant bacteria is a growing concern, and addressing this issue is crucial to effectively manage UTIs.

Public sector investments, often in the form of research grants, have been instrumental in fostering academic and government research initiatives aimed at improving UTI diagnosis and treatment. Public health organizations and governmental bodies recognize the economic and public health burden that UTIs pose and are actively investing in programs to reduce the prevalence of these infections. Public health campaigns are promoting awareness about UTIs and the importance of timely diagnosis and treatment. Additionally, governments are funding research into the epidemiology and microbiology of UTIs, leading to a better understanding of the causative agents and

their drug resistance patterns. Another key aspect of public sector involvement is the development of guidelines and regulations to ensure the responsible use of antibiotics in UTI treatment. Overuse and misuse of antibiotics have contributed to the development of drug-resistant strains, so regulating antibiotic prescribing practices is essential.

The investments made by both the private and public sectors in UTI testing and management are having a global impact. This is particularly important as UTIs are a widespread issue that knows no borders. Access to accurate diagnostics and effective treatments is improving not only in developed nations but also in resource-limited regions, where the burden of UTIs can be especially high.

Key Market Challenges

Overuse of Antibiotics

One of the major challenges facing the UTI testing market is the overuse of antibiotics, which can lead to the development of antibiotic-resistant strains of bacteria. UTIs are often treated empirically, with antibiotics prescribed before the results of a urine culture are available. This overreliance on antibiotics can contribute to the development of antibiotic-resistant bacteria, making treatment less effective in the long run.

Limited Awareness

While UTIs are common, there is a lack of awareness about the importance of proper testing and early diagnosis. Many individuals may self-diagnose and self-medicate without seeking professional medical advice. This limited awareness can lead to delayed diagnosis and treatment, resulting in more severe infections and complications.

False Positives and Negatives

Urinary tract infection testing methods, including dipstick tests and urinalysis, can yield false positives and false negatives. False positives may lead to unnecessary antibiotic treatment, contributing to antibiotic resistance. On the other hand, false negatives can result in missed diagnoses, leading to untreated infections that can worsen over time. Improving the accuracy of UTI testing methods is a critical challenge for the industry.

Lack of Standardization

The lack of standardized UTI testing procedures is another significant challenge. Different laboratories and healthcare facilities may use varying methods and interpret results differently, making it challenging to ensure consistency in UTI diagnosis. Standardization is crucial to ensure the accuracy and reliability of test results.

Cost Constraints

Cost constraints are a substantial challenge for both patients and healthcare providers. Comprehensive UTI testing, including urine culture and sensitivity testing, can be expensive. In resource-limited settings, cost can be a barrier to proper testing, leading to inadequate diagnosis and treatment.

Emerging Technologies

While new technologies are being developed to improve UTI testing, their adoption can be slow and face resistance from traditional testing methods. Healthcare providers may be hesitant to invest in new technologies due to the cost and the need for staff training. The transition from conventional methods to more advanced and accurate testing technologies is a challenge for industry.

Regulatory Hurdles

The global UTI testing market is subject to various regulatory hurdles, with different countries and regions having their own standards and requirements for diagnostic tests. Meeting these regulatory standards can be time-consuming and costly for manufacturers, hindering the availability of advanced testing methods in some areas.

Telemedicine and Remote Testing

The rise of telemedicine and remote testing options presents both opportunities and challenges. While these technologies can improve access to testing, they also raise concerns about the accuracy of remote testing and the potential for misdiagnosis. Ensuring that remote testing methods are accurate and reliable is a challenge that the industry must address.

Key Market Trends

Technological Advancements

Urinary tract infections (UTIs) are one of the most common bacterial infections affecting people of all ages. They can cause discomfort, pain, and even severe health complications if left untreated. The global urinary tract infection testing market has been evolving rapidly in recent years, thanks to the convergence of medical technology and innovative solutions. This market's growth is significantly driven by advancements in technology that have revolutionized the way UTIs are diagnosed, monitored, and treated.

The development of rapid point-of-care testing for UTIs has been a game-changer in healthcare. These tests are cost-effective, non-invasive, and deliver quick results, allowing for immediate diagnosis and treatment. Such technology often relies on innovative lab-on-a-chip devices, automated urinalysis equipment, and smartphone applications. Patients can now test for UTIs at home or at a clinic, leading to quicker interventions and better patient outcomes. Molecular diagnostic techniques, including polymerase chain reaction (PCR) and nucleic acid amplification, have significantly improved the accuracy and reliability of UTI testing. These methods can identify the specific strain of bacteria causing the infection, enabling healthcare providers to prescribe targeted antibiotics. Molecular diagnostics have also reduced the need for culture-based tests, which can take days to yield results.

The integration of digital health solutions, such as telemedicine and electronic health records, has streamlined the UTI testing process. Patients can consult with healthcare professionals remotely, receive electronic prescriptions, and monitor their condition through smartphone apps. These innovations improve the overall patient experience and reduce the burden on healthcare facilities. Artificial intelligence (AI) and machine learning (ML) algorithms are being used to analyze large datasets of UTI patient information. These technologies can assist healthcare professionals in diagnosing and predicting UTIs more accurately. They also help in the development of personalized treatment plans based on a patient's medical history and specific risk factors. The rise of wearable health devices, including smartwatches and fitness trackers, has also contributed to the growth of the UTI testing market. Some of these devices can monitor vital signs and urinary parameters, providing valuable data that can aid in the early detection of UTIs and prompt intervention.

Segmental Insights

Type Insights

Based on the category of type, Cystitis emerged as the dominant player in the global

market for Urinary Tract Infection Testing in 2022. Cystitis, often referred to as a lower UTI, is an infection or inflammation of the bladder. It is commonly caused by bacteria, such as *Escherichia coli* (*E. coli*), which can enter the bladder and lead to various symptoms, including frequent and painful urination, a strong urge to urinate, and discomfort in the pelvic region. Cystitis can affect individuals of all ages and genders, but it is more prevalent in women due to their shorter urethras, which make it easier for bacteria to reach the bladder. Accurate and timely diagnosis of cystitis is crucial for effective treatment and the prevention of complications. As a result, the global urinary tract infection testing market has seen a significant shift towards tests and diagnostic tools specifically designed to detect cystitis. Urine culture tests are among the most common methods for diagnosing cystitis. They involve growing and identifying bacteria in a urine sample to determine the cause of the infection. These tests not only confirm the presence of cystitis but also help in identifying the specific bacteria responsible, aiding in the selection of appropriate antibiotics. Rapid diagnostic tests are becoming increasingly popular as they provide quick results, often within minutes. These tests can detect specific proteins or DNA related to cystitis-causing bacteria. Their speed and accuracy are invaluable in clinical settings, allowing for prompt treatment and reducing the risk of complications.

End use Insights

The reference laboratories segment is projected to experience rapid growth during the forecast period. Reference laboratories are equipped with state-of-the-art technology and a wide range of diagnostic services. This includes the ability to perform culture tests, urinalysis, and molecular testing for various strains of bacteria responsible for UTIs. Their comprehensive approach allows for the accurate identification of pathogens and their antibiotic susceptibility profiles. Reference laboratories adhere to strict quality standards and regulations. These standards ensure the accuracy and reliability of test results, critical for patient care and public health. They are often accredited by organizations like the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP). Reference laboratories serve multiple healthcare providers, clinics, and hospitals. Their centralized testing approach means that they can handle a large volume of samples efficiently. This not only reduces the turnaround time for results but also offers cost-efficiency for both providers and patients.

Regional Insights

North America emerged as the dominant player in the global Urinary Tract Infection Testing market in 2022, holding the largest market share in terms of value. North

America, including the United States and Canada, has consistently reported a high prevalence of urinary tract infections. UTIs are one of the most common bacterial infections in the region, affecting millions of individuals every year. The prevalence of UTIs is driven by various factors, including lifestyle, diet, and healthcare infrastructure. The higher incidence of UTIs has led to a greater demand for UTI testing services. North America boasts some of the most advanced healthcare systems in the world. With well-established hospitals, clinics, and laboratories, the region has the infrastructure to support sophisticated diagnostic testing procedures. Patients have access to a wide range of healthcare services, including UTI testing, which contributes to the high demand for these tests.

Key Market Players

QIAGEN NV

Accelerate Diagnostics, Inc.

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche Ltd.

Danaher Corporation

Siemens Healthcare GmbH

Randox Laboratories Ltd.

Thermo Fisher Scientific, Inc.

BIOMERIEUX

T2 Biosystems, Inc.

Report Scope:

In this report, the Global Urinary Tract Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Urinary Tract Infection Testing Market, By Type:

Urethritis

Cystitis

Pyelonephritis

Urinary Tract Infection Testing Market, By End use:

Urologists

Urogynecologists

Hospital Laboratories

Reference Laboratories

Others

Urinary Tract Infection Testing Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Urinary Tract Infection Testing Market.

Available Customizations:

Global Urinary Tract Infection Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. GLOBAL URINARY TRACT INFECTION TESTING MARKET OUTLOOK

- 4.1. Market Size & Forecast
 - 4.1.1. By Value
- 4.2. Market Share & Forecast
 - 4.2.1. By Type (Urethritis, Cystitis, Pyelonephritis)
 - 4.2.2. By End use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Others)
 - 4.2.3. By Region
 - 4.2.4. By Company (2022)
- 4.3. Market Map

- 4.3.1. By Type
- 4.3.2. By End use
- 4.3.3. By Region

5. ASIA PACIFIC URINARY TRACT INFECTION TESTING MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Type
 - 5.2.2. By End use
 - 5.2.3. By Country
- 5.3. Asia Pacific: Country Analysis
 - 5.3.1. China Urinary Tract Infection Testing Market Outlook
 - 5.3.1.1. Market Size & Forecast
 - 5.3.1.1.1. By Value
 - 5.3.1.2. Market Share & Forecast
 - 5.3.1.2.1. By Type
 - 5.3.1.2.2. By End use
 - 5.3.2. India Urinary Tract Infection Testing Market Outlook
 - 5.3.2.1. Market Size & Forecast
 - 5.3.2.1.1. By Value
 - 5.3.2.2. Market Share & Forecast
 - 5.3.2.2.1. By Type
 - 5.3.2.2.2. By End use
 - 5.3.3. Australia Urinary Tract Infection Testing Market Outlook
 - 5.3.3.1. Market Size & Forecast
 - 5.3.3.1.1. By Value
 - 5.3.3.2. Market Share & Forecast
 - 5.3.3.2.1. By Type
 - 5.3.3.2.2. By End use
 - 5.3.4. Japan Urinary Tract Infection Testing Market Outlook
 - 5.3.4.1. Market Size & Forecast
 - 5.3.4.1.1. By Value
 - 5.3.4.2. Market Share & Forecast
 - 5.3.4.2.1. By Type
 - 5.3.4.2.2. By End use
 - 5.3.5. South Korea Urinary Tract Infection Testing Market Outlook
 - 5.3.5.1. Market Size & Forecast

- 5.3.5.1.1. By Value
- 5.3.5.2. Market Share & Forecast
 - 5.3.5.2.1. By Type
 - 5.3.5.2.2. By End use

6. EUROPE URINARY TRACT INFECTION TESTING MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Type
 - 6.2.2. By End use
 - 6.2.3. By Country
- 6.3. Europe: Country Analysis
 - 6.3.1. France Urinary Tract Infection Testing Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Type
 - 6.3.1.2.2. By End use
 - 6.3.2. Germany Urinary Tract Infection Testing Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Type
 - 6.3.2.2.2. By End use
 - 6.3.3. Spain Urinary Tract Infection Testing Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Type
 - 6.3.3.2.2. By End use
 - 6.3.4. Italy Urinary Tract Infection Testing Market Outlook
 - 6.3.4.1. Market Size & Forecast
 - 6.3.4.1.1. By Value
 - 6.3.4.2. Market Share & Forecast
 - 6.3.4.2.1. By Type
 - 6.3.4.2.2. By End use
 - 6.3.5. United Kingdom Urinary Tract Infection Testing Market Outlook

6.3.5.1. Market Size & Forecast

6.3.5.1.1. By Value

6.3.5.2. Market Share & Forecast

6.3.5.2.1. By Type

6.3.5.2.2. By End use

7. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type

7.2.2. By End use

7.2.3. By Country

7.3. North America: Country Analysis

7.3.1. United States Urinary Tract Infection Testing Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By End use

7.3.2. Mexico Urinary Tract Infection Testing Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

7.3.2.2.2. By End use

7.3.3. Canada Urinary Tract Infection Testing Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By End use

8. SOUTH AMERICA URINARY TRACT INFECTION TESTING MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

- 8.2.1. By Type
- 8.2.2. By End use
- 8.2.3. By Country
- 8.3. South America: Country Analysis
 - 8.3.1. Brazil Urinary Tract Infection Testing Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Type
 - 8.3.1.2.2. By End use
 - 8.3.2. Argentina Urinary Tract Infection Testing Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Type
 - 8.3.2.2.2. By End use
 - 8.3.3. Colombia Urinary Tract Infection Testing Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Type
 - 8.3.3.2.2. By End use

9. MIDDLE EAST AND AFRICA URINARY TRACT INFECTION TESTING MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Type
 - 9.2.2. By End use
 - 9.2.3. By Country
- 9.3. MEA: Country Analysis
 - 9.3.1. South Africa Urinary Tract Infection Testing Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Type
 - 9.3.1.2.2. By End use

9.3.2. Saudi Arabia Urinary Tract Infection Testing Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type

9.3.2.2.2. By End use

9.3.3. UAE Urinary Tract Infection Testing Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type

9.3.3.2.2. By End use

10. MARKET DYNAMICS

10.1. Drivers

10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

11.1. Recent Developments

11.2. Product Launches

11.3. Mergers & Acquisitions

12. GLOBAL URINARY TRACT INFECTION TESTING MARKET: SWOT ANALYSIS

13. PORTER'S FIVE FORCES ANALYSIS

13.1. Competition in the Industry

13.2. Potential of New Entrants

13.3. Power of Suppliers

13.4. Power of Customers

13.5. Threat of Substitute Product

14. COMPETITIVE LANDSCAPE

14.1. QIAGEN NV

14.1.1. Business Overview

- 14.1.2. Company Snapshot
- 14.1.3. Product & Services
- 14.1.4. Current Capacity Analysis
- 14.1.5. Financials (In case of listed)
- 14.1.6. Recent Developments
- 14.1.7. SWOT Analysis
- 14.2. Accelerate Diagnostics, Inc.
- 14.3. Bio-Rad Laboratories, Inc.
- 14.4. F. Hoffmann-La Roche Ltd.
- 14.5. Danaher Corporation
- 14.6. Siemens Healthcare GmbH
- 14.7. Randox Laboratories Ltd.
- 14.8. Thermo Fisher Scientific, Inc.
- 14.9. BIOM?RIEUX
- 14.10. T2 Biosystems, Inc.

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Urinary Tract Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Urethritis, Cystitis, Pyelonephritis), By End use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Others), By Region and Competition

Product link: <https://marketpublishers.com/r/U1DC12808B6CEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U1DC12808B6CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970